JP2016520050A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016520050A5 JP2016520050A5 JP2016512033A JP2016512033A JP2016520050A5 JP 2016520050 A5 JP2016520050 A5 JP 2016520050A5 JP 2016512033 A JP2016512033 A JP 2016512033A JP 2016512033 A JP2016512033 A JP 2016512033A JP 2016520050 A5 JP2016520050 A5 JP 2016520050A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- source
- nutritional composition
- acid
- egcg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 30
- 235000016709 nutrition Nutrition 0.000 claims 16
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 claims 11
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 claims 11
- 229940030275 epigallocatechin gallate Drugs 0.000 claims 11
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims 9
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims 9
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 150000001720 carbohydrates Chemical class 0.000 claims 4
- 238000007918 intramuscular administration Methods 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- NGEWQZIDQIYUNV-UHFFFAOYSA-N 2-hydroxy-3-methylbutyric acid Chemical compound CC(C)C(O)C(O)=O NGEWQZIDQIYUNV-UHFFFAOYSA-N 0.000 claims 2
- VEXDRERIMPLZLU-UHFFFAOYSA-N 3-hydroxy-2-methylbutanoic acid Chemical compound CC(O)C(C)C(O)=O VEXDRERIMPLZLU-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 230000001172 regenerating effect Effects 0.000 claims 2
- LVRFTAZAXQPQHI-RXMQYKEDSA-N (R)-2-hydroxy-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](O)C(O)=O LVRFTAZAXQPQHI-RXMQYKEDSA-N 0.000 claims 1
- ZMZQVAUJTDKQGE-UHFFFAOYSA-N 2-ethylhydracrylic acid Chemical compound CCC(CO)C(O)=O ZMZQVAUJTDKQGE-UHFFFAOYSA-N 0.000 claims 1
- DBXBTMSZEOQQDU-UHFFFAOYSA-N 3-hydroxyisobutyric acid Chemical compound OCC(C)C(O)=O DBXBTMSZEOQQDU-UHFFFAOYSA-N 0.000 claims 1
- QHKABHOOEWYVLI-UHFFFAOYSA-N 3-methyl-2-oxobutanoic acid Chemical compound CC(C)C(=O)C(O)=O QHKABHOOEWYVLI-UHFFFAOYSA-N 0.000 claims 1
- JVQYSWDUAOAHFM-UHFFFAOYSA-N 3-methyl-2-oxovaleric acid Chemical compound CCC(C)C(=O)C(O)=O JVQYSWDUAOAHFM-UHFFFAOYSA-N 0.000 claims 1
- QUKRTJQSGPLQKQ-UHFFFAOYSA-N 5-methylsulfonyl-3h-1,3-benzoxazol-2-one Chemical compound CS(=O)(=O)C1=CC=C2OC(=O)NC2=C1 QUKRTJQSGPLQKQ-UHFFFAOYSA-N 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- LVRFTAZAXQPQHI-UHFFFAOYSA-N alpha-hydroxyisocaproic acid Natural products CC(C)CC(O)C(O)=O LVRFTAZAXQPQHI-UHFFFAOYSA-N 0.000 claims 1
- 150000005693 branched-chain amino acids Chemical class 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 229960000310 isoleucine Drugs 0.000 claims 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004220 muscle function Effects 0.000 claims 1
- 230000009756 muscle regeneration Effects 0.000 claims 1
- 230000035764 nutrition Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000004474 valine Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818237P | 2013-05-01 | 2013-05-01 | |
| US61/818,237 | 2013-05-01 | ||
| PCT/US2014/036297 WO2014179526A1 (en) | 2013-05-01 | 2014-05-01 | Methods for enhancing aged muscle regeneration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016520050A JP2016520050A (ja) | 2016-07-11 |
| JP2016520050A5 true JP2016520050A5 (cg-RX-API-DMAC7.html) | 2017-06-01 |
Family
ID=50885012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016512033A Pending JP2016520050A (ja) | 2013-05-01 | 2014-05-01 | 老化筋肉再生の増強方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20160066610A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2999359A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016520050A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105188413A (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015027563A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2911471A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1221609A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2015015178A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12015502319A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201508388YA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014179526A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015094772A1 (en) * | 2013-12-18 | 2015-06-25 | Abbott Laboratories | Methods for increasing skeletal muscle protein synthesis using green tea extract |
| WO2016044272A1 (en) * | 2014-09-16 | 2016-03-24 | Abbott Laboratories | Methods of preserving muscle strength during a period of muscle disuse by administering beta-hydroxy-beta-methylbutyrate and green tea extract |
| JP6664956B2 (ja) * | 2015-02-27 | 2020-03-13 | キリンホールディングス株式会社 | 筋分化促進組成物 |
| WO2017048708A1 (en) * | 2015-09-16 | 2017-03-23 | Abbott Laboratories | Reduced fat, shelf stable liquid nutritional composition |
| CA3011364A1 (en) * | 2016-01-13 | 2017-07-20 | Metabolic Technologies, Inc. | Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) for joint stability |
| EP3435786B1 (en) * | 2016-04-01 | 2020-07-01 | DSM IP Assets B.V. | Beverages comprising stable granules of milled lutein |
| RU2018145520A (ru) | 2016-05-25 | 2020-06-25 | ТиЭсАй ГРУП ЛТД. | Стабилизация композиций бета-гидроксиизовалериановых кислот в мягких гелевых капсулах |
| US20210369674A1 (en) * | 2016-08-04 | 2021-12-02 | Seattle Gummy Company | Health management compositions and methods of making and using thereof |
| WO2018027079A1 (en) * | 2016-08-04 | 2018-02-08 | Seattle Gummy Company | Compositions for post-exercise recovery and methods of making and using thereof |
| US20210368843A1 (en) * | 2016-08-04 | 2021-12-02 | Seattle Gummy Company | Mineral compositions and methods of making and using thereof |
| US12370159B2 (en) | 2016-10-21 | 2025-07-29 | Metabolic Technologies, LLC | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) and probiotics |
| CA3041520A1 (en) * | 2016-10-21 | 2018-04-26 | Metabolic Technologies, Inc. | Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) and probiotics |
| WO2018224679A1 (en) | 2017-06-09 | 2018-12-13 | Philip Morris Products S.A. | Aerosol-generating article having fibrous filter segment |
| US20190037904A1 (en) * | 2017-08-04 | 2019-02-07 | Sean R. Daly | Food-based protein formulation |
| BR112020016178B1 (pt) | 2018-02-09 | 2023-03-14 | Haldor Tops0E A/S | Processo de produção de compostos alfa-hidroxi e seus usos |
| US20210227855A1 (en) * | 2018-06-23 | 2021-07-29 | Seattle Gummy Company | Methods and compositions for reducing caffeine side effects |
| JP6541047B1 (ja) * | 2018-10-18 | 2019-07-10 | 株式会社東洋新薬 | 経口組成物 |
| EP4117455A2 (en) * | 2020-03-10 | 2023-01-18 | The Regents of the University of California | Novel nutrients to enhance load-induced muscle hypertrophy |
| WO2021236440A1 (en) | 2020-05-20 | 2021-11-25 | Advanced Food Concepts, Inc. | Athletic performance enhancement composition using menthol |
| CN112568444A (zh) * | 2020-11-20 | 2021-03-30 | 格乐瑞(无锡)营养科技有限公司 | 一种缓解肌肉流失的组合物及其制备方法 |
| WO2023190293A1 (ja) * | 2022-03-30 | 2023-10-05 | ニュートリー株式会社 | とろみ状栄養組成物 |
| WO2025030001A2 (en) * | 2023-08-02 | 2025-02-06 | Abbott Laboratories | Methods and compositions for maintaining skeletal muscle mobility and/or mass, and/or for recovery of skeletal muscle strength |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7445807B2 (en) * | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
| US8329646B2 (en) * | 2005-11-30 | 2012-12-11 | Nestec S.A. | Methods for the treatment of muscle loss |
| CN101495146B (zh) * | 2006-04-07 | 2012-10-17 | 国立大学法人大阪大学 | 肌肉再生促进剂 |
| JP5507802B2 (ja) * | 2006-08-10 | 2014-05-28 | 花王株式会社 | 筋肉老化抑制剤 |
| RU2012105901A (ru) * | 2009-07-20 | 2013-08-27 | Нестек С.А. | Способы снижения потери функционального состояния |
| US20130338228A1 (en) * | 2010-12-27 | 2013-12-19 | Abbott Laboratories | Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate |
| WO2012097061A1 (en) * | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for improving skeletal muscle protein metabolism |
| WO2012097064A1 (en) * | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for controlling blood glucose |
-
2014
- 2014-05-01 US US14/888,314 patent/US20160066610A1/en not_active Abandoned
- 2014-05-01 MX MX2015015178A patent/MX2015015178A/es unknown
- 2014-05-01 HK HK16109844.1A patent/HK1221609A1/zh unknown
- 2014-05-01 BR BR112015027563A patent/BR112015027563A2/pt not_active IP Right Cessation
- 2014-05-01 EP EP14728386.5A patent/EP2999359A1/en not_active Withdrawn
- 2014-05-01 JP JP2016512033A patent/JP2016520050A/ja active Pending
- 2014-05-01 CA CA2911471A patent/CA2911471A1/en not_active Abandoned
- 2014-05-01 WO PCT/US2014/036297 patent/WO2014179526A1/en not_active Ceased
- 2014-05-01 CN CN201480024698.9A patent/CN105188413A/zh active Pending
- 2014-05-01 SG SG11201508388YA patent/SG11201508388YA/en unknown
-
2015
- 2015-10-06 PH PH12015502319A patent/PH12015502319A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016520050A5 (cg-RX-API-DMAC7.html) | ||
| ES2731899T3 (es) | Composición de vacuna nasal contra la gripe | |
| WO2018084531A3 (ko) | 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물 | |
| JP2014528914A5 (cg-RX-API-DMAC7.html) | ||
| DE60336934D1 (de) | Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten | |
| Yamagata et al. | Epigallocatechin-3-gallate inhibits VCAM-1 expression and apoptosis induction associated with LC3 expressions in TNFα-stimulated human endothelial cells | |
| JP2011225596A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0806392A8 (pt) | uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| CN111479580A (zh) | 采用自噬诱发剂和高蛋白质的组合来诱发自噬的组合物和方法 | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| CN104257970B (zh) | 一种外用跌打药膏 | |
| JP2017105859A5 (cg-RX-API-DMAC7.html) | ||
| WO2006078424A3 (en) | Polyherbal compositions and methods for treating viral infections | |
| JP2019529569A5 (cg-RX-API-DMAC7.html) | ||
| JP2016534062A5 (cg-RX-API-DMAC7.html) | ||
| JP2014505679A5 (cg-RX-API-DMAC7.html) | ||
| RU2013133998A (ru) | Способы и композиции для предотвращения и лечения остеоартрита | |
| HRP20150363T1 (hr) | Kompozicije koje sadrže core-1 pozitivni mikroorganizam i njihova primjena za lijeäśenje ili profilaksu tumora | |
| JP5775096B2 (ja) | インフルエンザの治療剤または予防剤 | |
| JP2015500836A5 (cg-RX-API-DMAC7.html) | ||
| JP2012180331A (ja) | 筋損傷の早期回復の誘導用の経口摂取剤 | |
| RU2014134989A (ru) | Добавка для матери, предназначенная для укрепления иммунной системы ребенка | |
| US20150164928A1 (en) | Pharmaceutical composition for the regeneration of the liver | |
| RU2464034C2 (ru) | Способ лечения туберкулеза, осложненного непереносимостью химиотерапии |